Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 15;29(6):1370–1378. doi: 10.1038/s41591-023-02347-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, Axial T1-weighted MR (top row) and FLAIR images (bottom row) obtained at baseline, 3 months, 6 months, 12 months and 38 months after infusion of DNX-2401 for one complete responder. b, The change of tumor size over time in each patient with a complete response. Dotted black line represents no change relative to baseline. Dashed red line represents the threshold for response according to the mRANO criteria. Both patients showed response to treatment at 3 months after DNX-2401 infusion, with complete response by 15–18 months.